For fiscal 2026 (ended Jun 30, 2026), Aytu BioPharma Inc. reported $57.57M of revenue and -$14.25M of net income.
AYTU revenue was $16.11M in fiscal Q4 2026 (ended Jun 30, 2026), up 6.4% from a year earlier and up 29.8% from the prior quarter. For the full fiscal 2026 it was $57.57M, down 13.3% from fiscal 2025. Compound annual growth was -2.6% over 5 years and +36.5% over 10 years. It rose in 8 of the last 10 fiscal years.
AYTU net income was -$15.0K in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$19.82M a year earlier. For the full fiscal 2026 it was -$14.25M, compared with -$13.56M in fiscal 2025.
AYTU diluted EPS was -$0.53 in fiscal Q3 2026 (ended Mar 31, 2026), compared with $0.21 a year earlier. For the full fiscal 2023 it was -$5.11.
AYTU free cash flow was $4.39M in fiscal Q4 2026 (ended Jun 30, 2026), up 57.7% from a year earlier. For the full fiscal 2026 it was $3.25M, compared with -$2.17M in fiscal 2025. Fiscal 2026 is the highest of the 12 fiscal years on file.
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.57M | $66.38M | $65.18M | $107.40M | $96.67M | $65.63M | $27.63M | $7.32M | $3.66M | $3.22M |
| Cost of revenue | $20.75M | $20.55M | $16.13M | $40.77M | $44.39M | $36.43M | $8.28M | $2.20M | $2.05M | $1.42M |
| Gross profit | $36.82M | $45.83M | $49.05M | $66.63M | $52.28M | $29.20M | $19.35M | $5.12M | $1.61M | $1.80M |
| Research and development | $0 | $1.33M | $2.77M | $4.09M | $12.66M | $5.62M | $1.72M | $589.1K | $167.6K | $959.9K |
| Selling, general and admin | $19.27M | $17.38M | $19.95M | $28.63M | $31.17M | $25.50M | $19.66M | $18.89M | $17.73M | $17.44M |
| Operating income | -$8.31M | -$7.83M | -$1.59M | -$17.07M | -$109.91M | -$58.87M | -$21.13M | -$16.85M | -$19.70M | -$20.13M |
| Interest expense | $1.90M | $3.70M | $5.06M | $4.96M | - | - | $2.61M | $535.5K | $749.4K | $2.53M |
| Pre-tax income | -$14.23M | -$13.74M | -$10.38M | -$17.05M | -$108.89M | -$58.03M | -$13.62M | - | - | - |
| Income tax | $21.0K | $437.0K | $2.14M | $0 | -$110.0K | $259.0K | $0 | $0 | $0 | $0 |
| Net income | -$14.25M | -$13.56M | -$15.84M | -$17.05M | -$108.78M | -$58.29M | -$13.62M | -$27.13M | -$10.19M | -$22.51M |
| EPS, basic | -$1.16 | -$2.16 | -$2.86 | -$5.11 | -$74.01 | -$69.60 | -$60.20 | -$696.00 | -$3062.00 | -$193200.00 |
| EPS, diluted | - | - | - | -$5.11 | -$74.01 | -$69.60 | -$60.20 | -$696.00 | -$3062.00 | -$193200.00 |
| Diluted shares | - | - | - | 3.3M | 1.5M | 837,333.95 | 225,960.05 | 38,972.445 | 3,328.025 | 116.506 |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $26.31M | $30.95M | $20.01M | $22.98M | $19.36M | $49.90M | $48.33M | $11.04M | $7.01M | $802.3K |
| Short-term investments | - | - | - | - | - | - | - | - | - | $0 |
| Receivables | $22.78M | $31.16M | $23.53M | $28.94M | $21.71M | $28.18M | $5.63M | $1.74M | $578.8K | $528.0K |
| Inventory | $6.86M | $11.43M | $12.14M | $11.99M | $10.85M | $16.34M | $10.00M | $1.44M | $1.34M | $1.31M |
| Current assets | $61.76M | $79.18M | $61.89M | $72.83M | $59.93M | $105.23M | $75.42M | $15.43M | $9.47M | $3.03M |
| Goodwill | - | - | - | $0 | $0 | $65.80M | $28.09M | $0 | - | $238.4K |
| Total assets | $105.01M | $124.18M | $118.09M | $136.46M | $137.62M | $265.67M | $153.29M | $34.72M | $21.06M | $15.00M |
| Current liabilities | $54.66M | $63.06M | $62.23M | $69.02M | $64.44M | $109.44M | $28.76M | $5.37M | $3.39M | $3.61M |
| Short-term debt | $1.86M | $1.86M | $1.86M | $85.0K | $3.81M | - | $982.1K | $0 | - | - |
| Long-term debt | $9.10M | $10.89M | $10.88M | $14.71M | $14.28M | $180.0K | $0 | - | - | - |
| Total debt | $10.96M | $12.75M | $12.73M | $14.80M | $18.09M | $180.0K | $982.1K | $0 | $0 | - |
| Total liabilities | - | - | - | $97.11M | $93.31M | $128.10M | $58.28M | $27.63M | $7.64M | $11.00M |
| Shareholders' equity | $35.27M | $18.97M | $27.72M | $39.36M | $44.31M | $137.57M | $95.02M | $7.09M | $13.42M | $4.00M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.28M | -$1.94M | -$1.39M | -$5.13M | -$28.82M | -$25.96M | -$28.37M | -$13.83M | -$15.94M | -$13.83M |
| Capital expenditures | $29.0K | $228.0K | $329.0K | - | $0 | $2.34M | $0 | $59.8K | $74.7K | $111.6K |
| Free cash flow | $3.25M | -$2.17M | -$1.72M | - | -$28.82M | -$28.30M | -$28.37M | -$13.89M | -$16.02M | -$13.94M |
| Investing cash flow | -$29.0K | -$2.56M | -$329.0K | -$117.0K | -$3.25M | -$2.78M | -$5.66M | -$1.06M | -$484.3K | -$3.53M |
| Financing cash flow | -$7.90M | $15.44M | -$1.26M | $8.87M | $1.53M | $30.31M | $71.07M | $19.08M | $22.66M | $10.19M |
| Stock-based compensation | $691.0K | $576.0K | $2.37M | $6.05M | $5.25M | $3.57M | $1.08M | $1.02M | $596.9K | $2.50M |
| Depreciation and amortization | $3.93M | $5.38M | $6.72M | $8.81M | $10.15M | $9.20M | $5.71M | $2.73M | $2.59M | $4.36M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -13.3% | 1.8% | -39.3% | 11.1% | 47.3% | 137.5% | 277.5% | 100.0% | 13.6% | 25.7% |
| Gross margin | 64.0% | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% | 70.0% | 69.9% | 44.0% | 56.0% |
| Operating margin | -14.4% | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% | -76.5% | -230.1% | -538.2% | -624.7% |
| Net margin | -24.8% | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -370.6% | -278.3% | -698.7% |
| Free cash flow margin | 5.6% | -3.3% | -2.6% | - | -29.8% | -43.1% | -102.7% | -189.8% | -437.6% | -432.7% |
| Return on equity | -40.4% | -71.5% | -57.2% | -43.3% | -245.5% | -42.4% | -14.3% | -382.8% | -75.9% | -562.7% |
| Return on assets | -13.6% | -10.9% | -13.4% | -12.5% | -79.0% | -21.9% | -8.9% | -78.1% | -48.4% | -150.1% |
| Current ratio | 1.13 | 1.26 | 0.99 | 1.06 | 0.93 | 0.96 | 2.62 | 2.87 | 2.79 | 0.84 |
| Debt to equity | 0.31 | 0.67 | 0.46 | 0.38 | 0.41 | 0.00 | 0.01 | 0.00 | 0.00 | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.11M | $12.41M | $15.16M | $13.89M | $15.13M | $18.45M | $16.22M | $16.57M | $14.59M | $14.03M | $18.75M | $17.82M |
| Cost of revenue | $5.70M | $4.81M | $5.54M | $4.70M | $4.88M | $5.65M | $5.43M | $4.59M | $3.54M | $3.66M | $4.14M | $4.78M |
| Gross profit | $10.41M | $7.60M | $9.62M | $9.19M | $10.25M | $12.81M | $10.79M | $11.98M | $11.05M | $10.36M | $14.60M | $13.04M |
| Research and development | $0 | $0 | $0 | $0 | $216.0K | $162.0K | $522.0K | $426.0K | $1.04M | $611.0K | $521.0K | $595.0K |
| Selling, general and admin | $4.30M | $4.97M | $5.07M | $4.92M | $3.70M | $4.11M | $4.45M | $5.13M | $4.03M | $4.83M | $4.80M | $6.29M |
| Operating income | -$777.0K | -$4.06M | -$1.97M | -$1.50M | -$7.62M | $2.42M | -$1.70M | -$930.0K | -$2.27M | -$1.60M | $3.15M | -$867.0K |
| Interest expense | $383.0K | $436.0K | $560.0K | $516.0K | $730.0K | $900.0K | $1.08M | $994.0K | $1.25M | $1.26M | $1.27M | $1.28M |
| Pre-tax income | -$4.0K | -$5.61M | -$10.58M | $1.97M | -$19.44M | $3.82M | $382.0K | $1.50M | -$2.54M | -$1.77M | $1.40M | -$7.47M |
| Income tax | $11.0K | $10.0K | $0 | $0 | $437.0K | -$122.0K | -$283.0K | $405.0K | $841.0K | $521.0K | $780.0K | $0 |
| Net income | -$15.0K | -$5.62M | -$10.58M | $1.97M | -$19.82M | $3.99M | $788.0K | $1.47M | -$4.62M | -$2.89M | -$220.0K | -$8.12M |
| EPS, basic | - | -$0.53 | -$1.05 | $0.21 | - | $0.65 | $0.13 | $0.24 | - | -$0.52 | -$0.04 | -$1.48 |
| EPS, diluted | - | -$0.53 | -$1.05 | -$0.08 | - | $0.21 | -$0.26 | -$0.15 | - | -$0.52 | -$0.04 | -$1.48 |
| Diluted shares | - | 10.5M | 10.0M | 19.5M | - | 8.2M | 8.5M | 9.1M | - | 5.5M | 5.5M | 5.5M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $26.31M | $26.71M | $30.02M | $32.63M | $30.95M | $18.17M | $20.40M | $20.11M | $20.01M | $19.76M | $19.53M | $19.96M |
| Receivables | $22.78M | $24.49M | $30.92M | $33.23M | $31.16M | $35.83M | $25.40M | $23.16M | $23.53M | $29.93M | $29.40M | $29.88M |
| Inventory | $6.86M | $7.46M | $8.66M | $10.10M | $11.43M | $11.06M | $11.09M | $11.74M | $12.14M | $13.19M | $13.00M | $12.97M |
| Current assets | $61.76M | $67.33M | $76.24M | $81.11M | $79.18M | $72.51M | - | - | $61.89M | $71.13M | $71.37M | $70.60M |
| Total assets | $105.01M | $111.69M | $122.00M | $124.99M | $124.18M | $124.20M | $116.23M | $115.83M | $118.09M | $128.86M | $131.25M | $132.89M |
| Current liabilities | $54.66M | $59.97M | $65.56M | $65.99M | $63.06M | $70.71M | $64.05M | $61.25M | $62.23M | $83.69M | $64.19M | $65.46M |
| Short-term debt | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $1.86M | $15.13M | $39.0K | $1.22M |
| Long-term debt | $9.10M | $9.55M | $10.00M | $10.45M | $10.89M | $9.54M | $9.98M | $10.43M | $10.88M | $0 | $14.98M | $14.84M |
| Total debt | $10.96M | $11.41M | $11.86M | $12.30M | $12.75M | $11.39M | $11.84M | $12.29M | $12.73M | $15.13M | $15.02M | $16.06M |
| Total liabilities | - | - | - | - | - | - | - | - | - | - | - | $100.72M |
| Shareholders' equity | $35.27M | $35.14M | $14.20M | $23.17M | $18.97M | $34.90M | $30.77M | $29.83M | $27.72M | $30.78M | $32.85M | $32.17M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.41M | -$4.18M | $3.67M | -$618.0K | $2.80M | -$6.46M | $2.90M | -$1.19M | -$788.0K | -$254.0K | -$135.0K | -$211.0K |
| Capital expenditures | $12.0K | $0 | $17.0K | $0 | $17.0K | $69.0K | $6.0K | $136.0K | $329.0K | $0 | - | - |
| Free cash flow | $4.39M | -$4.18M | $3.66M | -$618.0K | $2.79M | -$6.52M | $2.90M | -$1.33M | -$1.12M | -$254.0K | - | - |
| Investing cash flow | -$12.0K | $0 | -$17.0K | $0 | -$3.02M | -$69.0K | $145.0K | $381.0K | -$34.0K | -$45.0K | -$174.0K | -$76.0K |
| Financing cash flow | -$4.80M | $872.0K | -$6.26M | $2.30M | $12.99M | $4.30M | -$2.76M | $911.0K | $1.07M | $530.0K | -$126.0K | -$2.73M |
| Stock-based compensation | $146.0K | $148.0K | $283.0K | $114.0K | $113.0K | $139.0K | $151.0K | $173.0K | $242.0K | $811.0K | $820.0K | $930.0K |
| Depreciation and amortization | $1.12M | $1.12M | $885.0K | $803.0K | $1.46M | $1.29M | $1.29M | $1.33M | $1.56M | $1.83M | $1.90M | $2.23M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 6.4% | -32.7% | -6.5% | -16.2% | 3.7% | 31.6% | -13.5% | -7.0% | -52.5% | -38.3% | -28.7% | -35.6% |
| Net income growth, YoY | - | - | - | 33.3% | - | - | - | - | - | - | - | - |
| Gross margin | 64.6% | 61.2% | 63.5% | 66.1% | 67.8% | 69.4% | 66.5% | 72.3% | 75.7% | 73.9% | 77.9% | 73.2% |
| Operating margin | -4.8% | -32.7% | -13.0% | -10.8% | -50.4% | 13.1% | -10.4% | -5.6% | -15.6% | -11.4% | 16.8% | -4.9% |
| Net margin | -0.1% | -45.3% | -69.8% | 14.1% | -130.9% | 21.6% | 4.9% | 8.9% | -31.6% | -20.6% | -1.2% | -45.6% |
| Free cash flow margin | 27.3% | -33.7% | 24.1% | -4.4% | 18.4% | -35.4% | 17.9% | -8.0% | -7.7% | -1.8% | - | - |
| Current ratio | 1.13 | 1.12 | 1.16 | 1.23 | 1.26 | 1.03 | - | - | 0.99 | 0.85 | 1.11 | 1.08 |
| Debt to equity | 0.31 | 0.32 | 0.83 | 0.53 | 0.67 | 0.33 | 0.38 | 0.41 | 0.46 | 0.49 | 0.46 | 0.50 |
Source: XBRL data Aytu BioPharma Inc. files with the SEC, latest filing dated Sep 22, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Sep 1, 2016; 1-for-20, first reported Aug 31, 2017; 1-for-20, first reported Nov 7, 2018; 1-for-10, first reported Feb 11, 2021; 1-for-20, first reported Feb 21, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AYTU | $57.57M | -13.3% | -$14.25M | -24.8% | $19.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |